

Hepatic Function and its Association with Clinical Outcomes in Non-Adherent HIV-1 Adults

Brian Mutuma¹, Robin Omedo¹, Philemon Wafula^{2,3}, Norman Demba³, Jeremiah Zablon⁴, Nathan Shaviya¹, Tom Were⁵

¹Department of Medical Laboratory Sciences, School of Public Health Biomedical Sciences and Technology, Masinde Muliro University of Science and Technology, Kakamega, 50100 Kenya.

²Laboratory Department, Siaya County Teaching and Referral Hospital, Siaya, 40600, Kenya.

³Department of Medical Laboratory Sciences, School of Medicine, Maseno University, Kisumu, 40100, Kenya.

⁴Department of Immunology, Kenyatta National Hospital, Nairobi, 00100 Kenya.

⁵Department of Microbiology and Parasitology, School of Medicine, Masinde Muliro University of Science and Technology, Kakamega, 50100, Kenya.

Corresponding Author

Brian Mutuma

Mobile:

+254711939377

Email:

brianmutumaz7@gmail.com

©2023 The author (s).

Published by Zagazig University. This is an open-access article under the CC BY 4.0 license

<https://creativecommons.org/licenses/by/4.0/>

Receive date: 8/5/2023

Revise date: 8/5/2023

Accept date: 9/6/2023

Publish date: 1/9/2023

Keywords:

Hepatic function; Highly Active Antiretroviral Therapy; Human immunodeficiency virus – 1; non-adherence, clinical outcomes.

Background and study aim: Hepatic derangements are emerging as prominent causes of mortality and morbidity among HIV patients on Highly Active Antiretroviral therapy (HAART). Among this population, high HIV viremia, low CD4+ count, and HAART have been established as risk factors for hepatic injury. Although HAART mitigates these risks, it is unknown whether non-adherence to it contributes to the development of hepatic derangements. The current study aimed to explore whether non-adherence to HAART affects the hepatic function of HIV-1 infected adults and to associate hepatic function makers with Viral loads, Body mass index, and CD4+ counts of the same population.

Materials and Methods: This cross-sectional analytical study targeted HIV-1 infected adults on first-line HAART comprising Tenofovir Disoproxil Fumarate, Lamivudine, and Efavirenz. A total of 163 adult participants were enrolled. Adherence to HAART was

calculated using Pharmacy refill records. Hepatic enzyme levels were measured using a Mindray BS-200 automated clinical chemistry analyzer. Descriptive statistics, Kruskal Wallis test, and Bonferroni post hoc statistical tests were performed using SPSS version 25.

Results: Levels of total protein and globulin were elevated among HAART non-adherent participants relative to HAART adherent participants. Furthermore, Albumin to total protein and albumin to globulin ratios were lower in the HAART non-adherent participants relative to the HAART adherent group. CD4+ counts positively correlated with globulin levels. However, levels of Aspartate transaminase, Alanine transaminase, Alkaline phosphatase, and Gamma glutamyl transferase were similar between HAART non-adherent and HAART adherent participants.

Conclusion: Non-adherence to HAART dysregulates hepatic globulin synthesis without significant hepatic damage.

INTRODUCTION

The Human immunodeficiency virus (HIV) remains a threat to global public health. Approximately 84.2 million HIV infections and 40.1 million HIV-related mortalities have been reported globally since the onset of HIV [1]. Currently, the global HIV incidence stands at 1.5 million HIV infections totaling 38.4 million people living with HIV (PLHIV). Despite the

tremendous decline of HIV incidence in the Eastern and Southern Africa region, the region remains disproportionately affected and threatened by a slow HIV response [2]. HIV is also a public health concern in Kenya which bears a heterogeneous HIV burden largely clustered around the Lake Victoria basin [3]. Siaya County, located on the Lake Victoria basin bears an HIV prevalence of.

12.3%, ranking it among the top five counties with the highest HIV burden in Kenya [4].

HAART remains the global standard for HIV therapy and with optimal adherence it effectively suppresses viral replication to undetectable levels [5]. By 2021, approximately 28.7 million PLHIV worldwide received HAART of which 16.2 million were in the Eastern and Southern Africa region [6]. Approximately 83% of all PLHIV in Kenya have access to HAART [7]. Scale-up of HAART globally has led to a tremendous reduction in new HIV infections and a decline in HIV-related mortality over the past decade. Consequently, HIV has gradually evolved to a chronic manageable disease, and great improvement in the quality of life among PLHIV realized.

Contrary to earlier guidelines requiring initiation of HAART at CD4+ cell count < 200 cells/mm³, HAART is currently indicated in all patients who test positive for HIV regardless of their CD4+ count [8]. Consequently, HIV-related mortalities have decreased dramatically and lifespans of all PLHIV on HAART prolonged. However, the burden of non-HIV-related morbidity and mortality has drastically increased in the same population [9]. This is largely attributed to the development of systemic derangements such as Immune reconstitution inflammatory syndrome, metabolic dysregulation, nephrotoxicity, and hepatotoxicity after cumulative exposure to HAART [10].

Emerging evidence shows that liver-related derangements, common among PLHIV are among the leading determinants of non-HIV mortality [11]. Such derangements arise from liver damage caused by multiple stimuli, eventually translating into acute or chronic liver disease [12]. Among the HAART naive patients, high HIV viremia and low CD4+ counts mediate liver damage by promoting fibrogenesis and hepatocyte apoptosis [13]. HAART also advances structural liver damage via mitochondrial dysfunction, insulin resistance, hepatic steatosis, and fibrosis [14]. Although current antiretroviral agents used in HAART are effective in protecting against hepatic fibrosis, their efficiency is largely dependent on optimal adherence [15]. As such, non-adherence to HAART may predispose PLHIV to higher rates of liver derangements.

Liver injury among HIV-infected patients can be detected using liver enzyme levels. For instance,

among the HAART naive HIV patients, elevation of gamma-glutamyl transferase (GGT) and alkaline phosphatase (ALP) without underlying liver disease indicates HIV-mediated cholestatic liver damage [16]. Likewise, elevated levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) serve as indicators of hepatocellular injury among the same population. Hypoalbuminemia, consistent with HIV progression also occurs among HAART naive patients [17]. Among the HAART experienced, mild and self-limiting to severe transaminitis as well as hyperbilirubinemia is common [18]. Therefore, HAART non-adherent patients are at risk of hepatic damage from both HIV and HAART. Despite this, monitoring of liver damage among PLHIV at baseline and during follow-up remains inadequate, especially in resource-limited settings. WHO guidelines and Kenyan national guidelines on antiretroviral therapy only indicate non-mandatory determination of AST and ALT levels [19]. This hampers early detection, diagnosis, and management of liver injury among PLHIV.

Previously, associations between higher HIV viral loads with elevated AST and ALT have been reported among HIV patients with poorly controlled viremia, reflecting HIV-mediated liver injury [20]. In addition, low CD4+ counts are associated with an increased incidence of transaminitis and rapid progression of fibrosis among the same population. However, effective HAART counters hepatocyte fibrosis and inflammation, restoring levels of AST and ALT within normal ranges [21]. Furthermore, a higher body mass index (BMI) is associated with decreased risk of hypoalbuminemia among HIV-infected patients [22]. While these associations have been reported among HIV patients naive and adherent to HAART, it remains largely unknown whether they hold among HIV patients non-adherent to HAART. As such, the current study sought to evaluate the liver function of HAART non-adherent participants and associate them with viral load, BMI, and CD4+ counts.

MATERIALS AND METHODS

Study design: This was a cross-sectional analytical study.

Study site and population

This study was carried out among consenting HIV-1 adults attending Siaya County referral hospital, a public facility in Siaya County, Nyanza region of Kenya. Siaya has the third highest HIV burden of 15.3% after Kisumu (19.6%) and Homabay (17.5%) counties. It also bears the lowest levels of viral suppression among the three counties [4]. Study participants were enrolled through systematic random sampling.

Inclusion and exclusion criteria

Only individuals aged 18-60 years on a first-line HAART regime comprising Tenofovir, Lamivudine, and Efavirenz (TDF+3TC+EFV) for a period not less than 6 months were enrolled. The study excluded individuals with a history of hepatic, renal, or cardiovascular disease, tuberculosis, hepatitis B virus, hepatitis C virus, diabetes, hypertension, cancer, substance abuse, and pregnant women. Individuals on any other long-term medication other than HAART were also excluded. A total of 163 adults comprising HIV-1 negative (n=51), HAART naïve (n=23), HAART adherent (n=47), and HAART non-adherent (n=42) were recruited into the study. The sample size was determined using the Daniel (1999) formula and previously reported HIV prevalence [4].

Demographic and anthropometric measures

An open-ended questionnaire was used to collect demographic data of study participants. A Seca 786 (Hamburg, Germany) stadiometer was used to measure body weight and height with participants wearing light clothes and standing in an upright posture. Weight measurement was made to the nearest gram and height to the nearest centimeter. Body mass index (BMI, kg/m²) was calculated by dividing weight (kg) by height (m) and categorized into underweight (<18.5 kg/m²) normal (18.5 – 24.9 kg/m²), and overweight (>25.0 kg/m²) BMI groups based on World Health Organization (WHO) adult nutrition status.

Sample collection and processing.

An experienced phlebotomist collected 5ml of venous blood from the participants' antecubital vein into a syringe. 3ml of the blood was transferred into an Ethylenediamine tetraacetic acid vacutainer (EDTA) and 2ml into plain BD vacutainer® tubes (Becton Dickinson, Franklin Lakes, USA). The tubes were then labeled with the participant's code, date, and sample

collection time. Blood samples in EDTA tubes were used for CD4+ T cell enumeration immediately after collection. Blood in plain vacutainer tubes was allowed to clot for five minutes before serum extraction by centrifugation at 3000 r.p.m for 5 minutes. The obtained serum was used for hepatic function tests.

HIV-1 diagnosis.

Confirmation of HIV-1 was done using the rapid immunochromatographic test kit, Determine™ (Abbott Laboratories, Tokyo, Japan), and first response (Trinity Biotech Plc, Bray, Ireland). According to the Kenyan national HIV testing algorithm, Participants were considered HIV-1 infected if they had HIV-positive results for Determine and HIV-1 positive results using first response kits.

Clinical chemistry measurements

Liver function tests were run using an automated Mindray™ BS-200 Clinical Chemistry analyzer (Mindray Medical Intl, Shenzhen, China) as per the manufacturer's instructions and standard operation procedures. Quality controls for selected liver function tests were done and parameters that failed were recalibrated. Briefly, 1000ul of Serum was pitted into new, clean, unused Mindray™ BS-200 cuvettes and loaded inside the sample chamber of the machine. Subsequently, measurement of serum Aspartate Aminotransferase, Alanine aminotransferase, Albumin, Total Protein, Gamma Glutamyl transpeptidase, and C-reactive protein levels was done using the same machine.

Calculation of adherence to HAART

Adherence to HAART was assessed using comprehensive care clinic pharmacy refill records and percentage adherence was calculated using the following formula.

$$\text{Percentage adherence} = \frac{(\text{No. of doses patient should have taken} - \text{No. of doses missed}) \times 100}{\text{No. of doses the patient should have taken.}}$$

CD4+ T cell counts

The levels of CD4+ T cells were determined using a Pima™ point of care CD4 cytometer (Inverness medical™, Morges, Switzerland). 25.0 µl of well-mixed whole blood sample collected in EDTA BD vacutainer® tube was placed in the Pima CD4 test cartridge sample collector, capped, and inserted into the Pima™

CD4 cytometer. Enumeration of CD4+ T cells was based on the quantification of fluorescent signals emitted by fluorescent-labeled anti-CD3 and CD4-specific monoclonal antibodies interacting with the sample in the cartridge. The total signals collected were converted into a CD4+ count displayed as cells/ μ l within 20 minutes. CD4+ counts were then classified into various HIV immunological stages of HIV as follows; ≥ 500 CD4+ cells/ μ l as Stage I, 350 – 499 cells/ μ l as Stage II, 200 – 349 cells/ μ l as Stage III, and < 200 cells/ μ l as stage IV according to WHO guidelines.

HIV viral load determination

Viral load was determined using an automated Abbott m2000 System (Abbott Molecular Inc., Illinois, USA). RNA was extracted from 200 μ l of serum sample. Reverse transcription of the RNA to cDNA was done followed by amplification of the cDNA using HIV-specific primers. The extract was fed into the analyzer which converted the intensity of HIV probes to viral loads. WHO guidelines were used to categorize viral loads with viral loads < 1000 HIV-RNA copies/ml indicating viral suppression.

Statistical analysis

The data was analyzed using IBM SPSS version 25.0 (SPSS Inc. Chicago, USA). Categorical variables such as gender and duration of HAART were summarized into proportions and tabulated. Continuous variables (laboratory measures, age, height, weight, BMI) were described using medians (IQR). The chi-square test was used to determine differences in proportions. Kruskal Wallis test was used to compare continuous data across the study groups followed by Bonferroni post hoc correction for multiple comparisons. Spearman correlation test was used to determine the association of each liver function marker with the viral load, CD4+ count, and BMI.

RESULTS

Demographic and laboratory characteristics of study participants

A total of 163 adult participants comprising of males, (n = 73) and females (n = 90) were enrolled in the study. Of these, there were HIV-1 negative healthy controls (n= 51), HIV-1 positive HAART naive, (n=23), HIV-1 positive HAART adherent (n = 47), and HIV-1 positive HAART

non-adherent (n = 42). A summary of the demographic characteristics of study participants is presented in **Table I**. Age ($P = 0.838$) and height ($P = 0.465$) of study participants were similar across study groups but body weight differed across the study groups ($P = <0.0001$). HAART non-adherent participants (median, 59.1 kg; IQR, 11.8; $P < 0.0001$) weighed less than the HAART adherent group (median, 66.6 kg; IQR, 14.7). However, the HAART adherent group (median, 66.6 kg; IQR, 14.7; $P < 0.0001$) weighed more than the HAART naive group (median, 56.9 kg; IQR, 11.0). Likewise, body mass index (BMI) varied across groups ($P = <0.0001$) with the HAART non-adherent group (median, 21.1 kgm^2 ; IQR, 3.72; $P = 0.002$) having lower BMI than the HIV-1 HAART adherent group (median, 23.5 kgm^2 ; IQR, 5.49). In addition, the HAART non-adherent group (median, 21.1 kgm^2 ; IQR, 3.72; $P < 0.0001$) and HIV-1 HAART naive (median, 20.4 kgm^2 ; IQR, 5.11; $P = 0.003$) had lower BMI compared to HIV-1 negative healthy control group (median, 24.5 kgm^2 ; IQR, 5.27).

The distribution of participants into underweight, normal, and overweight BMI varied significantly across the groups ($P = <0.0001$). The majority of underweight participants were found in the HAART non-adherent while overweight participants were most frequent in the healthy control group. Varied distribution of participants amongst various CD4+ T cell categories was observed ($P = <0.0001$). The HAART non-adherent group accounted for the majority of participants in WHO stage III. Similarly, the distribution of participants between viral load categories differed significantly across the groups ($P < 0.0001$). The proportion of participants with low viral loads was highest in the HAART adherent group while the HAART non-adherent group had the highest proportion of participants with high viral loads.

Liver function parameters of study participants

Albumin levels varied significantly across groups ($P < 0.0001$) and were higher in the HAART non-adherent group (median, 3.6 g/dl; IQR, 1.7; $P = 0.008$) and HAART adherent group (median, 4.0 g/dl; IQR, 1.1; $P < 0.0001$) compared to the naive group (median, 3.2 g/dl; IQR, 1.2). **Table II** summarizes the liver function parameters of study participants. Likewise, globulin levels differed across the groups ($P < 0.0001$) with the HAART non-

adherent group having higher globulin levels (median, 3.4 g/dl; IQR, 1.9; $P < 0.0001$) relative to the HAART adherent group (median, 2.1 g/dl; IQR, 1.2). In addition, both the HAART adherent and HAART non-adherent groups had lower globulin compared to the HAART naive group (median, 3.4 g/dl; IQR, 1.9; $P = 0.006$ and median, 2.1 g/dl; IQR, 2.1; $P < 0.0001$ versus median, 4.1 g/dl; IQR, 1.0) respectively.

Total protein levels differed significantly among the groups ($P < 0.0001$) with between-group analysis showing elevated levels of total proteins in the HAART non-adherent group (median, 7.3 g/dl; IQR, 0.8; $P < 0.0001$) compared to the HAART adherent group (median, 6.5 g/dl; IQR, 0.6). In contrast, the HAART adherent group (median, 6.5 g/dl; IQR, 0.6; $P < 0.0001$) had lower total protein levels relative to the HAART naive (median, 7.5 g/dl; IQR, 1.0;) and healthy control group (median, 7.1 g/dl; IQR, 1.1). Levels of AST differed significantly across groups ($P < 0.0001$) and were higher in the HAART non-adherent (median, 31.6 IU/L; IQR, 8.0; $P < 0.0001$), HAART adherent (median, 32.6 IU/L; IQR, 12.4; $P < 0.0001$) and HAART naive (median, 33.3 IU/L; IQR, 9.8; $P < 0.0001$) relative to the healthy control group (median, 23.9 IU/L; IQR, 13.4). Likewise, levels of alanine aminotransferase (ALT) differed significantly across the groups ($P = 0.003$) with the HAART non-adherent group (median, 29.0 IU/L; IQR, 14.6; $P < 0.0001$) having higher ALT levels relative to the healthy control group (median, 25.0 IU/L; IQR, 9.9).

The activity of GGT and ALP varied significantly in a similar fashion across groups at the same level of statistical significance ($P < 0.0001$). GGT activity was significantly higher in HAART non-adherent group (median 42.4 IU/L; IQR, 34.3; $P < 0.0001$), HAART adherent group

(median 51.7 IU/L; IQR, 32.0; $P < 0.0001$) and in HAART naive group (median 46.3 IU/L; IQR, 31.0; $P < 0.0001$) in comparison to the healthy control group (median 28.0 IU/L; IQR, 25.3). Similarly, ALP activity was higher in the HAART non-adherent group (median 100.8 IU/L; IQR, 27.0; $P < 0.0001$), HAART adherent group (median 108.7 IU/L; IQR, 27.6; $P < 0.0001$) and in HAART naive group (median 102.5 IU/L; IQR, 31.0; $P < 0.0001$) in comparison to HIV negative healthy controls (median 28.0 IU/L; IQR, 25.3).

Albumin, total protein, globulin, ALT, and AST ratios of study participants.

Across-group analysis revealed significant variations in albumin to total protein ratio ($P < 0.0001$) as shown in **Table II**. Subsequent between-group analysis revealed lower albumin to total protein values in the HAART non-adherent group (median, 0.5; IQR, 0.2; $P < 0.0001$) compared to the HAART adherent group (median, 0.6; IQR, 0.1). In contrast, albumin to total protein ratio was significantly higher in the HAART non-adherent (median, 0.5; IQR, 0.2; $P = 0.009$) and HAART adherent group (median, 0.6; IQR, 0.1; $P < 0.0001$) in comparison to the HAART naive group (median, 0.4; IQR, 0.1). Similarly, values of albumin to globulin ratio were significantly higher in the HAART adherent group (median, 0.6; IQR, 0.1; $P = 0.003$) relative to the healthy control group (median, 0.5; IQR, 0.1).

Correlation of liver function with clinical Outcomes HIV-1 HAART non-adherent

There was a weak significant positive correlation between globulin levels with CD4+ counts ($\rho = 0.308$, $P = 0.048$) among HIV-1 HAART non-adherent participants as shown in **Table III**.

Table I: Demographic and laboratory characteristics of study participants

Characteristic	HIV-1 [-] Control (n = 51)	HIV-1 [+] HAART naive (n = 23)	HIV-1 [+] HAART adherent, (n = 47)	HIV-1 [+] HAART non- adherent, (n = 42)	P-value
Gender:					
Female n (%)	27 (52.9)	14 (60.9)	32 (68.1)	17 (40.5)	
Male, n (%)	24 (47.1)	9 (39.1)	15 (31.9)	25 (59.5)	0.065
Age, years	37.0 (6.0)	38.0 (7.0)	37.0 (7.0)	36.5 (9.3)	0.838
Height, m	1.7 (0.1)	1.7 (0.1)	1.7 (0.1)	1.7 (0.1)	0.465
Weight, Kg	67.8 (18.0)	56.9 (11.0) ^a	66.6 (14.7) ^b	59.1 (11.8) ^{a,c}	<0.0001
BMI, Kg/m ²	24.5 (5.27)	20.4 (5.11) ^a	23.5 (5.49)	21.1 (3.72) ^{a,c}	<0.0001
BMI category, n (%)					
Underweight (<18.5kg/m ²)	4 (7.8)	3 (13.0)	3 (6.4)	9 (21.4)	
Normal (18.5 – 24.9 kg/m ²)	22 (43.1)	16 (69.6)	26 (55.3)	30 (71.4)	<0.0001
Overweight (>25.0 kg/m ²)	25 (49.0)	4 (17.4)	18 (38.3)	3 (7.1)	
WHO HIV immunological staging, n (%)					
Stage III	0 (0.0)	10 (43.5)	5 (10.6)	18 (42.8)	
Stage II	3 (5.9)	7 (30.4)	13 (27.7)	12 (28.6)	<0.0001
Stage I	48 (94.1)	6 (26.1)	29 (61.7)	12 (28.6)	
Log ₁₀ HIV-1 RNA, Copies/ml	0 (0.0)	4.5 (1.6)	3.4 (1.9) ^a	4.6 (1.1) ^{b,c}	<0.0001
Viral Load Categories, n (%)					
Low	0 (0.0)	4 (17.4)	20 (42.6)	3 (7.3)	<0.0001
High	0 (0.0)	19 (82.6)	27 (57.4)	38 (92.7)	

Data shown are numbers (n) and proportion (%) of study subjects for categorical variables and median, interquartile range (IQR) for continuous variables. HIV-1 [-]; Human immunodeficiency virus type 1 negative. HIV-1 [+]; Human immunodeficiency virus type 1 positive. HAART; Highly active antiretroviral therapy, BMI; Body mass index. Data analysis was conducted using chi-square tests for proportions and the Kruskal-Wallis test for continuous data. Thereafter, the Bonferroni post-hoc test was used for comparisons between study groups. Bonferroni correction was set at $P < 0.0125$ and significant groups denoted as; ^a $P < 0.0125$ vs HIV-1[-] control, ^b $P < 0.0125$ vs HIV-1 [-] naive, ^c $P < 0.0125$ vs HIV-1 [+] HAART adherent. *P* values in bold are significant.

Table II: Liver function parameters of study participants

Parameter	HIV-1 [-] healthy control n = 51	HIV-1 [+] HAART naive n = 23	HIV-1 [+] HAART adherent, n = 47	HIV-1 [+] HAART non-adherent, n = 42	<i>P</i>
Liver function parameters					
Albumin, g/dl	4.0 (3.0-5.4)	3.2 (2.1-4.5) ^a	4.3 (2.7-5.8) ^b	3.6 (2.6-5.6) ^b	<0.0001
Globulin, g/dl	3.2 (3.0-5.4)	4.1 ((2.3-6.1) ^a	2.1 (0.5-3.7) ^{a,b}	3.4 (1.2-5.1) ^{b,c}	<0.0001
Total protein, g/dl	7.1 (6.0-8.4)	7.5 (6.8-8.2)	6.5 (5.6-7.3) ^{a,b}	7.3 (6.6-8.0) ^c	<0.0001
ALB/T.PROT ratio	0.5 (0.4-0.8)	0.4 (0.3-0.6) ^a	0.6 (0.4-0.9) ^{a,b}	0.5 (0.3-0.8) ^{b,c}	<0.0001
ALB/GLB ratio	1.2 (0.6-4.7)	0.8 (0.3-1.8)	2.1 (0.7-11.2) ^{a,b}	1.1 (0.5-4.8) ^c	<0.0001
AST, IU/L	23.9 (9.1-36.9)	33.3 (19.1- 42.3) ^a	32.6 (18.8-45.0) ^a	31.6 (21.6-42.7) ^a	<0.0001
ALT, IU/L	25.0 (11.4-37.4)	25.4 (15.6-36.4)	29 (14.8-43.9) ^a	28.8 (15.7-35.3)	0.003
AST/ALT ratio	1.0 (0.3-2.6)	1.2 (0.7-2.1)	1.1 (0.5-2.2)	1.2 (0.6-2.1)	0.025
GGT, IU/L	28.0 (9.4-48.0)	46.3 (22.6-73.5) ^a	51.7 (28.2-84.7) ^a	42.4 (23.4-73.6) ^a	<0.0001
ALP, IU/L	74.4 (43.1-115.6)	102.5 (68.1-130.2) ^a	108.7 (64.1-133.9) ^a	100.8 (72.2-132.8) ^a	<0.0001

Data shown are median, and interquartile range (IQR) for continuous variables of study subjects. HIV-1 [-]; Human immunodeficiency virus type 1 negative. HIV-1 [+]; HIV-1 positive. HAART; Highly active antiretroviral therapy. AST; Aspartate aminotransferase. ALT; Alanine aminotransferase. GGT; Gamma-glutamyl transpeptidase. ALP; Alkaline phosphatase. IU/L; international units per liter. Data analysis was conducted using the Kruskal-Wallis test. Thereafter, the Bonferroni post-hoc test was used for comparisons between study groups. Bonferroni correction was set at $P < 0.0125$ and significant groups denoted as ^a $P < 0.0125$ vs HIV-1[-] control, ^b $P < 0.0125$ vs HIV-1 [-] naive, ^c $P < 0.0125$ vs HIV-1 [+] HAART adherent. *P* values in bold are significant.

Table III. Correlation of liver function with Clinical outcome measures HIV-1 HAART non-adherent

Parameter	BMI, kg		Viral loads		CD4+ count	
	ρ	<i>P</i>	ρ	<i>P</i>	ρ	<i>P</i>
Total protein, g/dl	-0.272	0.081	-0.183	0.246	0.064	0.688
Albumin	0.113	0.476	0.158	0.318	-0.214	0.173
Globulin	-0.214	0.173	-0.275	0.078	0.308	0.048
ALB: GLB ratio	0.157	0.322	0.209	0.185	-0.249	0.112
ALB: T.PRT ratio	0.157	0.322	0.209	0.185	-0.249	0.112
AST, IU/L	0.201	0.203	-0.111	0.485	0.131	0.408
ALT, IU/L	-0.054	0.735	0.164	0.298	-0.211	0.179
AST: ALT ratio	0.150	0.342	-0.194	0.218	0.278	0.074
ALP, IU/L	-0.036	0.819	0.195	0.216	-0.169	0.285
GGT, IU/L	0.129	0.414	0.202	0.199	-0.229	0.145

Data presented are correlation coefficients (rho, ρ) with associated p-values. Statistical analysis was performed using Spearman's rank correlation test. BMI; body mass index, ALB/GLB ratio; albumin-to-globulin ratio, ALB/T.PRT ratio; albumin-to-total protein ratio, AST; Aspartate aminotransferase, ALT; Alanine aminotransferase, ALP; alkaline phosphatase, GGT; gamma-glutamyl transferase.

DISCUSSION

Non-adherence to HAART is a global public health concern associated with HIV progression and transmission [23]. In the current era of widespread HAART use, non-AIDS-related conditions are emerging as the leading causes of mortality among PLHIV with liver diseases being amongst the most profound determinants of mortality [11]. While both HAART and HIV are known to contribute to liver injury, the role of non-adherence to HAART in the emergence of liver injury among PLHIV remains poorly characterized. Therefore, the current study determined liver function markers among HIV-1 HAART non-adherent and adherent adults from western Kenya.

Significantly lower weight and BMI as well as higher rates of underweight BMI among HAART non-adherent participants relative to the HAART adherent counterparts were indicative of HIV-induced malnutrition. Furthermore, higher viral loads and higher rates of participants with HIV immunological stage III in the HAART non-adherent group indicated poor viral suppression and HIV progression. The findings resonate with previous studies done in Uganda and Ethiopia [24]. Non-adherence to HAART results in suboptimal suppression and promotes HIV progression, ultimately predisposing HAART non-adherent patients to HIV-associated malnutrition, poor nutrient absorption and

utilization as well as metabolic disturbances resulting in weight loss [25]. Plausibly, malnutrition may have also resulted from food insecurity is identified as a predictor of non-adherence to HAART.

Elevated albumin levels in the HAART non-adherent and HAART adherent groups relative to the HAART naive group suggest improved hepatic albumin synthesis. This finding corroborates previous studies indicating a significant increase in albumin levels upon initiation to HAART [26]. HAART suppresses HIV viral replication and promotes immune restoration, ultimately improving hepatic synthetic function [27]. Although albumin is a negative acute phase protein whose levels decline with HIV progression, no significant difference was revealed in albumin levels between HAART adherent and non-adherent groups. It is possible that the interaction between HIV and HAART as well as albumin's long half-life prevented sharp declines in albumin levels among the HAART non-adherent group [28]. As such, our findings suggest that the use of HAART, regardless of adherence to it, among PLHIV promotes the liver's synthetic function.

Elevation of globulin and total protein levels as well as viral load levels among the HAART non-adherent participants was indicative of disease progression. Increases in globulins are attributable to dysregulated globulin synthesis

resulting from poor viral suppression, common among HAART non-adherent patients [29]. As such, high viral loads impair hepatic and B-cell functions and promote hepatocyte inflammation leading to overproduction of α , β , and gamma globulins, subsequently elevating globulin levels [30]. Consequently, albumin to globulin ratio is reduced among HAART non-adherent patients as the case with the present study. Our findings are consistent with previous studies that observed elevation of globulin levels among HAART naive individuals, suggesting that hyperglobulinemia observed among HAART non-adherent participants was HIV-induced [31]. As such, increased globulin levels and reduced albumin-to-globulin ratio present possible surrogate markers for the prediction of hepatic damage among HAART non-adherent patients.

In contrast with our findings, earlier studies associate HAART with a reduction of total protein levels [32]. This is explained by HAART's ability to dysregulate protein metabolism and induce adverse gastrointestinal disturbances which result in malnutrition. However, this effect may vary depending on adherence to HAART. Notably, effective HAART decreases globulin levels via immune reconstitution and rectification of dysregulated immune function with subsequent restoration of immunoglobulin levels [33]. In addition, indirect evidence showing lower levels of IgG and IgA among virally suppressed HIV-infected patients but not among viremic patients, suggests that adherence to HAART may play a role in dysregulating globulin levels [34]. Since poor viral suppression and progressive liver damage result in sustained globulin overproduction, our findings indicate that adherence to HAART modulates total protein levels by promoting elevation of globulin levels.

Elevation of AST levels among HIV-infected participants naive, adherent, and non-adherent to HAART relative to healthy controls suggests synergistic HIV and HAART-induced liver injury. This is supported in part by significantly higher ALT levels in the HAART adherent group relative to the healthy control group. Together, our findings imply that HIV progression and use of HAART can cause transaminitis. This corroborates previous studies conducted elsewhere (35). HIV directly injures hepatocytes via induction of apoptosis while antiretroviral agents such as Efavirenz induce mild to

moderate hepatotoxicity [36]. Elevation of ALT in the HAART adherent group alone suggested that HAART is a significant determinant of liver damage among PLHIV. Similar findings have been reported in Ethiopia [37]. Our findings differ from previous studies demonstrating marked elevation of AST and ALT among HIV patients on HAART [38], probably due to the exclusion of participants coinfecting with viral hepatitis, and tuberculosis as well as those with a history of alcohol consumption.

Concurrent elevation of GGT and ALP among the HAART non-adherent, adherent, and naive groups relative to HIV-1 negative healthy controls was indicative of progression to cholestasis and ongoing liver damage. Similar findings have been reported by earlier studies [39]. We attribute elevations of GGT and ALP to HIV infection and HAART. For instance, HIV-infected Kupffer cells, while mitigating gut microbial translocation in HIV, inadvertently trigger hepatic inflammatory and fibrogenic processes, ultimately causing hepatic damage [40]. In addition, HAART induces mitochondrial dysfunction and mitochondrial toxicity by promoting unregulated production of reactive oxygen species and impairment of intracellular drug metabolism which causes hepatic cholestasis.

Significant positive correlation of globulin levels with CD4+ counts as well as higher total protein and viral loads among HAART non-adherent participants was indicative of deranged B cell function and HIV progression. This finding partially resonates with a Nigerian study that reported a positive correlation between CD4+ count and α -1 macroglobulin [41]. Poor viral suppression among HAART non-adherent patients is associated with partial immune reconstitution, progressive liver damage, and sustained globulin overproduction by B cells [42]. It's also possible that CD4+ autoantibody production previously reported among virologically suppressed HIV-infected patients, may have been heightened among HAART non-adherent patients, ultimately resulting in hypergammaglobulinemia and dysregulated B-cell activation.

CONCLUSION

Non-adherence to HAART is associated with alterations of globulin, total protein, albumin to globulin, and albumin to total protein ratios

possibly indicating dysregulation of hepatic globulin synthesis but without significant hepatic damage. Further prospective studies on the value of globulin, total protein, and albumin to globulin indices as surrogate markers for non-adherence to HAART are warranted.

ACKNOWLEDGEMENT.

Our sincere gratitude goes to all participants who took part in this study.

Funding sources: None .

Conflict of interest: None.

Ethical consideration

Scientific and ethical approval for this study was obtained from Masinde Muliro University of Science and Technology Ethical Review Board (MMUST IERC), approval number **MMUST/IERC012/2022**, and the National Commission for Science, Technology and Innovation (NACOSTI), license number **NACOSTI/P/22/16221**. Written informed consent was obtained before enrollment in the study and confidentiality was maintained via coding and restricting access to study participants' information. Random selection of participants ensured equal chances of benefit for all. Free health education on the importance of proper adherence to HAART and the clinical consequences of non-adherence to HAART were given to all participants.

HIGHLIGHTS

1. Hepatic derangements are emerging as the leading cause of mortality among HIV patients on HAART.
2. High HIV viremia, low CD4+ count, and HAART are associated with the development of hepatic derangements among HIV patients.
3. Non-adherence to HAART was found to dysregulate hepatic globulin synthesis without causing significant hepatic damage.

REFERENCES

1. UNAIDS. Global HIV & AIDS statistics — Fact sheet [Internet]. 2021 [cited 2022 Jul 8]. Available from: <https://www.unaids.org/en/resources/fact-sheet>
2. UNAIDS. Full report — In Danger: UNAIDS Global AIDS Update 2022 [Internet]. 2022 [cited 2022 Nov 23]. Available from:

<https://www.unaids.org/en/resources/documents/2022/in-danger-global-aids-update>

3. UNAIDS. UNAIDS data 2021 [Internet]. 2021 [cited 2022 Nov 25]. Available from: https://www.unaids.org/en/resources/documents/2021/2021_unaids_data
4. NASCOP. KENPHIA [Internet]. PHIA Project. 2020 [cited 2021 May 22]. Available from: <https://phia.icap.columbia.edu/kenya-preliminary-report/>
5. Semvua SK, Orrell C, Mmbaga BT, Semvua HH, Bartlett JA, Boule AA. Predictors of non-adherence to antiretroviral therapy among HIV infected patients in northern Tanzania. *PLoS ONE* [Internet]. 2017 Dec 18 [cited 2020 Jul 8];12(12). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5734684/>
6. UNAIDS. Fact sheet - Latest global and regional statistics on the status of the AIDS epidemic. [Internet]. 2022 [cited 2022 Nov 26]. Available from: https://www.unaids.org/en/resources/documents/2022/UNAIDS_FactSheet
7. NACC. HIV statistics-Kenya [Internet]. National AIDS Control Council. 2021 [cited 2022 Dec 19]. Available from: <https://nacc.or.ke/>
8. WHO. Consolidated guidelines on HIV prevention, testing, treatment, service delivery, and monitoring: recommendations for a public health approach [Internet]. 2021 [cited 2022 Jul 21]. Available from: <https://www.who.int/publications-detail-redirect/9789240031593>
9. Gheibi Z, Shayan Z, Joulaei H, Fararouei M, Beheshti S, Shokoohi M. Determinants of AIDS and non-AIDS related mortality among people living with HIV in Shiraz, southern Iran: a 20-year retrospective follow-up study. *BMC Infect Dis*. 2019 Dec 30;19(1):1094.
10. Gebremicael G, Tola HH, Gebreegziaxier A, Kassa D. Incidence of Hepatotoxicity and Factors Associated During Highly Active Antiretroviral Therapy in People Living with HIV in Ethiopia: A Prospective Cohort Study. *HIVAIDS Auckl NZ*. 2021 Mar 25;13:329–36.
11. Benedicto AM, Fuster-Martínez I, Tosca J, Esplugues JV, Blas-García A, Apostolova N. NNRTI, and Liver Damage: Evidence of Their Association and the Mechanisms Involved. *Cells*. 2021 Jul 4;10(7):1687.

12. Mohammed O, Alemayehu E, Bisetegn H, Tilahun M, Gedefie A, Ebrahim E, et al. Prevalence of hepatotoxicity among HIV-infected patients in Ethiopia: a systematic review and meta-analysis. *BMC Infect Dis*. 2022 Nov 9;22(1):826.
13. Nina Kim H, Nance R, Van Rompaey S, Delaney JC, Crane HM, Cachay ER, et al. Poorly Controlled HIV Infection: An Independent Risk Factor for Liver Fibrosis. *J Acquir Immune Defic Syndr* 1999. 2016 Aug 1;72(4):437–43.
14. Chwiki S, Campos MM, McLaughlin ME, Kleiner DE, Kovacs JA, Morse CG, et al. Adverse Effects of Antiretroviral Therapy on Liver Hepatocytes and Endothelium in HIV Patients: an Ultrastructural Perspective. *Ultrastruct Pathol*. 2017;41(2):186–95.
15. Chamroonkul N, Bansal MB. HIV and the liver. *Nat Rev Gastroenterol Hepatol*. 2019 Jan;16(1):1–2.
16. Berchmas MJ, Francois NN. Role of Gamma Glutamyltransferase and Alkaline Phosphatase Assay in Enzymatic Panel for Hepatobiliary Function in Patients Attending Kibungo Hospital, Rwanda. *East Afr Sci*. 2020 Apr 24;2(1):81–7.
17. Barasa E, Were T, Budambula V, Shaviya N. rs1445776009 variants in the human ALB gene: Association with serum albumin and clinical outcomes in HIV-infected Kenyan injection substance users. *Int J Health Sci*. 2021 May 16;15.
18. Anyaike C, Atoyebi OA, Musa OI, Bolarinwa OA, Durowade KA, Ogundiran A, et al. Adherence to combined Antiretroviral therapy (cART) among people living with HIV/AIDS in a Tertiary Hospital in Ilorin, Nigeria. *Pan Afr Med J* [Internet]. 2019 Jul 1 [cited 2022 Jul 21];32(10). Available from: <https://www.panafrican-med-journal.com/content/article/32/10/full>
19. NASCOP. Guidelines on Use of Antiretroviral Drugs for Treating and Preventing HIV Infection in Kenya [Internet]. 2014 [cited 2022 Dec 23]. Available from: <http://guidelines.health.go.ke/#/category/4/152/meta>
20. Mata-Marín JA, Gaytán-Martínez J, Grados-Chavarría BH, Fuentes-Allen JL, Arroyo-Anduiza CI, Alfaro-Mejía A. Correlation between HIV viral load and aminotransferases as liver damage markers in HIV infected naive patients: a concordance cross-sectional study. *Virology*. 2009 Oct 30;6(1):181.
21. Forrester JE, Rhee MS, McGovern BH, Sterling RK, Knox TA, Terrin N. The Association of HIV Viral Load with Indirect Markers of Liver Injury. *J Viral Hepat*. 2012 Feb;19(2):e202–11.
22. Dusingize JC, Hoover DR, Shi Q, Mutimura E, Rudakemwa E, Ndacyayisenga V, et al. Association of Abnormal Liver Function Parameters with HIV Serostatus and CD4 Count in Antiretroviral-Naive Rwandan Women. *AIDS Res Hum Retroviruses*. 2015 Jul;31(7):723–30.
23. Bbosa N, Kaleebu P, Ssemwanga D. HIV subtype diversity worldwide. *Curr Opin HIV AIDS*. 2019 May;14(3):153–60.
24. Odwee A, Kasozi KI, Acup CA, Kyamanywa P, Ssebuufu R, Obura R, et al. Malnutrition amongst HIV adult patients in selected hospitals of Bushenyi district in southwestern Uganda. *Afr Health Sci*. 2020 Mar;20(1):122–31.
25. Daka DW, Ergiba MS. Prevalence of malnutrition and associated factors among adult patients on antiretroviral therapy follow-up care in Jimma Medical Center, Southwest Ethiopia. *PLoS ONE*. 2020 Mar 12;15(3):e0229883.
26. Chong JJ, Fragaszy E, Dukes O, Cason J, Kozlakidis Z. Serum Albumin Concentrations in a Multi-Ethnic Cohort of Patients with Human Immunodeficiency Virus Infection from South East London. *BioResearch Open Access*. 2015;4(1):160–3.
27. Liu J, Wang L, Hou Y, Zhao Y, Dou Z, Ma Y, et al. Immune restoration in HIV-1-infected patients after 12 years of antiretroviral therapy: a real-world observational study. *Emerg Microbes Infect*. 2020 Dec;9(1):2550–61.
28. Scherzer R, Heymsfield SB, Rimland D, Powderly WG, Tien PC, Bacchetti P, et al. Association of serum albumin and aspartate transaminase with 5-year all-cause mortality in HIV/hepatitis C virus coinfection and HIV mono-infection. *AIDS Lond Engl*. 2017 Jan 2;31(1):71–9.
29. Tanaka S, Okamoto Y, Yamazaki M, Mitani N, Nakajima Y, Fukui H. Significance of hyperglobulinemia in severe chronic liver diseases - With special reference to the correlation between serum globulin/IgG level and ICG clearance. *Hepatogastroenterology*. 2007 Dec 1;54:2301–5.

30. Badura R, Foxall RB, Ligeiro D, Rocha M, Godinho-Santos A, Trombetta AC, et al. Early ART in Acute HIV-1 Infection: Impact on the B-Cell Compartment. *Front Cell Infect Microbiol.* 2020;10:347.
31. Dang LVP, Pham VH, Nguyen DM, Dinh TT, Nguyen TH, Le TH, et al. Elevation of immunoglobulin levels is associated with treatment failure in HIV-infected children in Vietnam. *HIVAIDS - Res Palliat Care.* 2018 Dec 27;11:1–7.
32. Marceline DN, Justin WS, Luther KMM, Calixte PI, Rosalie NNA. Serum protein electrophoresis as an added value for disease control among HIV patients in a hospital setting in Cameroon. *J AIDS HIV Res.* 2018 Nov 30;10(7):103–9.
33. Yang X, Su B, Zhang X, Liu Y, Wu H, Zhang T. Incomplete immune reconstitution in HIV/AIDS patients on antiretroviral therapy: Challenges of immunological non-responders. *J Leukoc Biol.* 2020 Apr;107(4):597–612.
34. Redgrave BE, Stone SF, French M a. H, Krueger R, James IR, Price P. The effect of combination antiretroviral therapy on CD5 B- cells, B-cell activation and hypergammaglobulinaemia in HIV-1-infected patients. *HIV Med.* 2005 Sep;6(5):307–12.
35. Tesfa E, Siefu D, Belayneh Y, Mekonnen Z. Liver enzyme elevation in patients taking HAART compared with treatment naïve controls at Debre Berhan Referral Hospital: a comparative cross-sectional study, Northeast Ethiopia. *BMC Res Notes* [Internet]. 2019 Oct 30 [cited 2020 Jul 16];12. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822479/>
36. Puri P, Sharma PK, Lolusare A, Sashindran VK, Shrivastava S, Nagpal AK. Liver Function Tests Abnormalities and Hepatitis B Virus & Hepatitis C Virus Co-infection in Human Immunodeficiency Virus (HIV)-infected Patients in India. *J Clin Exp Hepatol.* 2017 Mar;7(1):1–8.
37. Shiferaw MB, Tulu KT, Zegeye AM, Wubante AA. Liver Enzymes Abnormalities among Highly Active Antiretroviral Therapy Experienced and HAART Naïve HIV-1 Infected Patients at Debre Tabor Hospital, North West Ethiopia: A Comparative Cross-Sectional Study. *AIDS Res Treat* [Internet]. 2016 [cited 2020 Jul 16];2016. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4963552/>
38. Iddi S, Minja CA, Silago V, Benjamin A, Mpesha J, Henerico S, et al. High Human Immunodeficiency Virus (HIV) Viral Load and Coinfection with Viral Hepatitis Are Associated with Liver Enzyme Abnormalities among HIV Seropositive Patients on Antiretroviral Therapy in the Lake Victoria Zone, Tanzania. *AIDS Res Treat.* 2019 Jun 2;2019:e6375714.
39. Nsonwu-Anyanwu A, Offor S, King D, Chidozie A, Egbe E, Eyong W, et al. Highly Active Antiretroviral Therapy Related Changes in Renal and Liver Functions in HIV Infection. *International Journal of Biomedical Laboratory Science (IJBS)* 2017 Vo1. 6, No. 1&2:6-11.
40. Nganou-Makamdop K, Talla A, Sharma AA, Darko S, Ransier A, Laboune F, et al. Translocated microbiome composition determines immunological outcomes in treated HIV infection. *Cell.* 2021 Jul 22;184(15):3899-3914.e16.
41. Igwe CU, Ewuga EE, Ujowundu CO, Onyeocha IO, Onwuliri VA. Serum protein concentration and amino acid profile of HIV/HBV co-infected subjects on HAART in Plateau State, Nigeria. *Afr Health Sci.* 2022 Apr 29;22(1):418–30.
42. Xu W, Luo Z, Alekseyenko AV, Martin L, Wan Z, Ling B, et al. Distinct systemic microbiome and microbial translocation are associated with plasma levels of anti-CD4 autoantibody in HIV infection. *Sci Rep.* 2018 27;8(1):12863.

Cite as: Mutuma, B., Omedo, R., Wafula, P., Demba, N., Zablou, J., Shaviya, N., Were, T. Hepatic Function and its Association with Clinical Outcomes in Non-Adherent HIV-1 Adults . *Afro-Egyptian Journal of Infectious and Endemic Diseases*, 2023; 13(3): 146-156. doi: 10.21608/aeji.2023.188741.1288